Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA - Eisenberger, M; Hardy-Bessard, A C; Kim, C S (J Clin Oncol, 2017)
. doi:10.1200/jco.2016.72.1076